Barnes P J, Chung K F
Department of Thoracic Medicine, National Heart and Lung Institute, London, UK.
Trends Pharmacol Sci. 1992 Jan;13(1):20-3. doi: 10.1016/0165-6147(92)90011-t.
The safety of the most widely prescribed antiasthma drugs, beta 2-adrenoceptor agonists, has recently been questioned. Issues such as their suitability for long-term and regular prophylactic use are addressed in this Comment article by Peter Barnes and Fan Chung, who examine the possibility that the beta 2-agonists themselves contribute to worsening symptoms in asthma patients, thus setting up a vicious circle with greater use of the drugs. They conclude that it would be prudent to restrict the use of beta 2-agonists in asthma to on-demand immediate symptom control.
最常用的抗哮喘药物β2肾上腺素受体激动剂的安全性最近受到了质疑。彼得·巴恩斯和范·钟在这篇评论文章中探讨了诸如它们是否适合长期和常规预防性使用等问题，他们研究了β2激动剂本身是否会导致哮喘患者症状恶化的可能性，从而形成一个恶性循环，导致更多地使用这些药物。他们得出结论，将β2激动剂在哮喘治疗中的使用限制于按需即时控制症状是谨慎的做法。
